10-K: Monopar Therapeutics Advances Wilson Disease, Oncology Programs

Monopar Therapeutics reports progress in its Wilson disease and radiopharmaceutical oncology programs, backed by a recent $91.9 million capital raise and extended cash runway through 2027.

Summary

• Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.
• ALXN1840, an investigational once-daily oral drug for Wilson disease, holds Orphan Drug Designation in the U.S. and EU, and Fast Track designation from the FDA.
• Monopar licensed ALXN1840 exclusively worldwide in October 2024, despite Alexion's prior termination of the program due to Phase 2 mechanistic trial results, not safety signals.
• Long-term efficacy and safety data for ALXN1840, presented at EASL and ANA in 2025, demonstrated sustained neurological and hepatic improvements, and rapid, sustained improvement in daily copper balance.
• The MNPR-101 radiopharmaceutical programs, including MNPR-101-Zr for imaging and MNPR-101-Lu for therapy, are in Phase 1 clinical trials in Australia for advanced cancers expressing uPAR, with MNPR-101-Ac in late preclinical stage.
• The FDA cleared the Investigational New Drug (IND) application for MNPR-101-Lu on September 26, 2025, and an Expanded Access Program (EAP) for MNPR-101-Zr and MNPR-101-Lu is open in Houston, Texas.
• Cash, cash equivalents, and investments totaled $140.4 million as of December 31, 2025, with current funds expected to be sufficient through December 31, 2027.
• The net loss for 2025 was $(13.7) million, an improvement from $(15.6) million in 2024, while operating loss increased to $(16.7) million from $(16.2) million.
• Research and development expenses decreased by $3.1 million in 2025, primarily due to the absence of one-time in-licensing expenses for ALXN1840 in 2024, partially offset by increased personnel and manufacturing costs.
• General and administrative expenses increased by $3.6 million in 2025, mainly due to higher Board compensation and personnel expenses.
• A public offering in September 2025, combined with pre-funded warrants, generated approximately $91.9 million in net proceeds after a $35 million share repurchase from Tactic Pharma LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant clinical progress and a strong financial position with an extended cash runway, despite the historical termination of ALXN1840 by Alexion and ongoing operational losses. The advancement of multiple programs and successful capital raise are key strengths.

Positives

• ALXN1840's pivotal Phase 3 trial met its primary endpoint, demonstrating three-times greater copper mobilization compared to standard-of-care (LSM Diff 2.18 mol/L; p< 0.0001).
• ALXN1840 showed sustained improvements in neurological and patient-reported symptoms (UWDRS Part II and Part III) over 6 years, and statistically significant psychiatric improvement over multiple years.
• Patients who transitioned from standard-of-care to ALXN1840 exhibited additional neurological improvement, with a majority reversing previously worsened symptoms.
• ALXN1840 demonstrated a favorable safety profile with less than 5% drug-related serious adverse events and less than 1% drug-related neurological serious adverse events across over 645 patient-years.
• Positive early clinical data for MNPR-101-Zr validated its tumor-targeting ability and showed significant uptake in an ovarian cancer patient.
• FDA clearance for the IND application for MNPR-101-Lu enables further clinical development in the U.S.
• The Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu provides early access to investigational treatments for patients with advanced solid tumors.
• The company maintains a strong cash position of $140.4 million as of December 31, 2025, with an expected cash runway through December 31, 2027.
• Net loss decreased from $(15.6) million in 2024 to $(13.7) million in 2025.
• Interest income significantly increased to $2.988 million in 2025 from $0.404 million in 2024, reflecting effective cash management.
• New patent filings for radiopharmaceutical compounds and linkers could expand the proprietary pipeline and enhance competitive advantage.

Negatives

• Alexion terminated the ALXN1840 program based on Phase 2 mechanistic trials failing to demonstrate net-negative copper balance and reduced hepatic copper concentration, despite positive Phase 3 results.
• The company has a limited operating history and has incurred cumulative losses of approximately $89.5 million since inception through December 31, 2025.
• General and Administrative (G&A) expenses increased by $3.6 million in 2025, primarily due to higher Board compensation and personnel expenses.
• Operating loss increased to $(16.7) million in 2025 from $(16.2) million in 2024.
• The company relies heavily on third-party contract manufacturers for all raw materials, active pharmaceutical ingredients (APIs), and finished drug products for both ALXN1840 and MNPR-101 programs, exposing it to potential delays and compliance inadequacies.
• The MNPR-101 radiopharmaceutical manufacturing vendor was acquired by a competitor, and long-term manufacturing contracts are not secured, posing a supply risk.
• As a small organization with limited resources, the company lacks a dedicated cybersecurity organization or employee personnel with specific cybersecurity expertise.
• Some key MNPR-101 patents are nearing expiration (composition of matter in 2027, epitope in 2029), which could reduce competitive protection.
• The company has no approved products on the market and has not generated any revenue from product sales to date.

Risks

• Inability to raise sufficient additional funding on acceptable terms to support continued clinical, regulatory, and commercial development, and to make contractual future milestone payments.
• Uncertain outcomes for the ALXN1840 regulatory package and NDA submission, with potential for the FDA to require additional studies or deny approval.
• Radiopharmaceuticals are a relatively novel approach, which may create significant and unpredictable challenges, including radioisotope availability, potential misconceptions about safety, and low market uptake.
• The time-limited shelf-life of radiopharmaceutical drug candidates poses fulfillment and logistical challenges, potentially leading to delays or inability to meet demand.
• Reliance on third-party contract manufacturers for critical materials and drug products exposes the company to potential delays, compliance inadequacies, and supply chain disruptions.
• Termination of third-party licenses (e.g., Alexion for ALXN1840, XOMA for MNPR-101) could adversely affect rights to important compounds or technologies.
• Market variables, such as inflation of product costs, labor rates, fuel, freight, energy costs, and tariffs, could significantly increase operating and administrative expenses.
• Unstable market and economic conditions (e.g., volatility in financial markets, bank instability, economic recession) may limit the company's ability to raise funds.
• Geopolitical events (Russia-Ukraine war, Israel-Hamas conflict, developments in Venezuela, U.S.-Israel-Iran conflict, instability in Persian Gulf states) could increase supply costs, delay manufacturing, restrict radioisotope availability, and introduce financing difficulties.
• Resurgences of COVID-19 or other pandemics could disrupt clinical programs, manufacturing, and regulatory processes.
• Intense competition from larger, better-financed biotechnology and pharmaceutical companies, and academic institutions, potentially making product candidates obsolete or non-competitive.
• Loss of key management leadership or scientific personnel could materially disrupt the business and delay product development.
• Computer system failures, cyber-attacks, or deficiencies in cybersecurity could increase expenses, divert management attention, and adversely affect results of operations.
• Product liability claims, which may not be adequately covered by insurance, could result in significant liabilities and reputational harm.
• Market opportunities for current and potential future drug candidates may be smaller than estimated, adversely affecting revenue generation.
• Intellectual property disputes could require significant time and money, limit intellectual property rights, or force redesigns of products.
• Patent terms may be inadequate to protect the company's competitive position for a sufficient amount of time, leading to earlier competition from generic medications.
• Failure to comply with health and data protection laws and regulations (e.g., HIPAA, GDPR, CCPA) could lead to government enforcement actions, private litigation, or adverse publicity.
• Future legislation or executive or private sector actions related to healthcare reform could increase commercialization costs and adversely affect product pricing.
• Politically divided governmental actions and related political actions outside of government can impact the FDA's role in the timely and effective review of new pharmaceutical products.
• Future tax reform measures may negatively impact the company's financial position.
• Foreign currency exchange rates may adversely affect consolidated financial statements.
• Existing and new investors will experience dilution as a result of future sales or issuances of common stock, future exercises of pre-funded warrants, and future option exercises.
• The stock price of common stock may be volatile or may decline regardless of operating performance.
• Anti-takeover provisions in corporate documents and Delaware law could make a merger, tender offer, or proxy contest difficult, thereby depressing the potential trading price of common stock.
• The ability to use net operating loss (NOL) carryforwards and certain other tax attributes may be limited under Section 382 of the Code due to ownership changes.

Future Outlook

The company expects to submit its New Drug Application (NDA) for ALXN1840 in mid-2026, incorporating additional information and refining the submission package. It plans to continue and conclude the Phase 1 imaging/dosimetry clinical trial for MNPR-101-Zr, continue the Phase 1a therapeutic clinical trial for MNPR-101-Lu, and advance the preclinical MNPR-101-Ac program into the clinic. The company also intends to invest in internal R&D projects to expand its radiopharmaceutical pipeline and anticipates needing additional significant funding to commercialize ALXN1840 and complete the MNPR-101 radiopharmaceutical clinical programs, expecting R&D and SG&A expenses to increase for pre-commercialization and commercialization activities.

Management Comments

• "We are committed to maintaining governance and oversight of these risks and to implementing standard operating procedures (SOPs) and training to help us assess, identify, monitor and respond to these risks." (Regarding cybersecurity)
• "Our Board has ultimate oversight of cybersecurity risks and has established a cybersecurity committee headed by our former Chief Financial Officer who is a member of our Board."
• "We aim to incorporate industry best practices for companies of our size and financial strength throughout our cybersecurity program."
• "We are now fully responsible for the program [ALXN1840], including its commercial advancement and compliance with all applicable federal regulations."
• "Together, we believe these findings [ANA data] underscore the potential of ALXN1840 to favorably impact both neurological and hepatic manifestations of Wilson disease."
• "Our management team has extensive experience in developing therapeutics and medical technologies through global regulatory approval and commercialization."
• "Understanding the preclinical, clinical, regulatory and commercial development processes and hurdles are key factors in successful drug development, and the expertise demonstrated by our management team across all of these areas increases the probability of success in advancing the product candidates in our product pipeline."
• "Our strategic goal is to acquire, develop, and commercialize innovative treatments for patients with unmet medical needs."
• "We anticipate that the currently available funds as of March 17, 2026, will fund our planned operations at least through December 31, 2027."

Industry Context

StockSavvy.ai notes that the radiopharmaceutical space has seen significant positive developments, including four major acquisitions since December 2023 with upfront payments ranging from approximately $1 billion to over $4 billion (BMS/RayzeBio, AstraZeneca/Fusion Pharma, Eli Lilly/POINT BioPharma, and Novartis/Mariana Oncology). This trend highlights strong industry interest and investment in targeted radiopharmaceuticals, positioning Monopar's MNPR-101 program within a rapidly growing and attractive sector. The company's focus on uPAR, highly expressed in aggressive cancers, aligns with the industry's pursuit of precision oncology.

Comparison to Industry Standards

• ALXN1840's Phase 3 trial demonstrated three-times greater copper mobilization compared to standard-of-care (SoC), suggesting a significant improvement over existing treatments like penicillamine-based products (Cuprimine, Depen) and trientine-based products (Syprine, Cuvrior), and zinc acetate (Galzin, Wilzin).
• MNPR-101's preclinical data showing high, selective, and durable uptake in human tumor xenograft mouse models for triple-negative breast, colorectal, and pancreatic tumors, along with promising anti-tumor activity with lutetium-177 and actinium-225, positions it favorably against other targeted radiopharmaceuticals in development by companies such as Novartis AG, Bayer AG, Bristol Myers Squibb, Eli Lilly and Company, and AstraZeneca.
• The use of one of the world's most sensitive clinical total-body PET/CT scanners (Siemens Biograph Vision Quadra) for MNPR-101-Zr imaging in Australia indicates a commitment to high-standard clinical development, comparable to leading research institutions globally.
• The company's management team has a strong track record, having co-founded BioMarin Pharmaceutical, Sensant Corp., American BioOptics, Raptor Pharmaceuticals ($800 million sale to Horizon Therapeutics), and Wilson Therapeutics (acquired by Alexion for $764 million), indicating a level of expertise and success that exceeds that of many early-stage biopharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not, and to date has never been, a party to any adverse material legal proceedings.

Related Party Transactions

• Repurchased 500,229 shares of common stock from Tactic Pharma LLC for $35 million on September 24, 2025. Chandler D. Robinson, CEO and Board member, is a minority owner and non-controlling Managing Member of Tactic Pharma.
• Entered into a consulting agreement with pRx Consulting, LLC, effective January 1, 2026, for $2,000 per month and stock options. Dr. Patrice Rioux, president of pRx Consulting, LLC, is a director of Monopar's French subsidiary.

Stakeholder Impact

• Shareholders face potential for dilution from future equity offerings and warrant exercises, stock price volatility, and reliance on stock appreciation for returns as no dividends are paid. Anti-takeover provisions may limit their ability to influence management or the Board.
• Patients with Wilson disease may benefit from a new, effective once-daily oral treatment (ALXN1840) with demonstrated sustained neurological and hepatic benefits, offering an alternative to existing standard-of-care therapies.
• Patients with advanced cancers may gain access to investigational radiopharmaceutical imaging (MNPR-101-Zr) and therapeutic agents (MNPR-101-Lu) through ongoing clinical trials and an Expanded Access Program, targeting aggressive uPAR-expressing tumors.
• Employees may see increased R&D and G&A personnel expenses, including stock-based compensation, indicating growth and investment in human capital, but also face the risk of program delays if key personnel are lost.
• Creditors face uncertainty regarding the company's ability to generate revenue and achieve profitability, as it relies on future funding and product approvals.
• Suppliers and contract manufacturers will continue to be critical partners, but the company's reliance on third parties for raw materials and drug products carries risks of delays and compliance issues, exacerbated by a radiopharmaceutical vendor acquisition by a competitor.

Next Steps

• Assemble a regulatory package and submit an NDA for ALXN1840 in mid-2026.
• Continue to conduct and conclude the first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr.
• Continue to conduct the first-in-human therapeutic clinical trial of MNPR-101-Lu.
• Advance the preclinical MNPR-101-Ac program into the clinic.
• Invest in internal R&D projects to expand the radiopharmaceutical pipeline.
• Identify and potentially invent or license novel targets and drug candidates complementing radiopharmaceutical and rare disease programs.
• Seek regulatory approvals for any current and future drug product candidates that successfully complete registration clinical trials.
• Establish or purchase the services of a sales, marketing, and distribution infrastructure to commercialize any products for which marketing approval is obtained.
• Develop or contract for manufacturing/quality capabilities or establish a reliable, high-quality supply chain sufficient to support clinical requirements and to provide sufficient capacity to launch and supply the market for any approved product.
• Add or contract for required operational, financial, and management information systems and capabilities and other specialized expert personnel to support drug product candidate development, pre-commercial, and planned commercialization efforts.

Key Dates

Recommendation

Monopar Therapeutics shows promising clinical progress with ALXN1840 for Wilson disease and its MNPR-101 radiopharmaceutical programs, backed by a solid cash position and extended runway. However, the historical termination of ALXN1840 by Alexion, the inherent risks of clinical development, intense competition, and the company's history of losses warrant a cautious approach. The upcoming NDA submission for ALXN1840 in mid-2026 and further clinical data from MNPR-101 programs are key catalysts, but also carry significant regulatory and market uncertainties. Investors should hold to monitor these critical developments.

Keywords

Wilson disease, radiopharmaceuticals, oncology, ALXN1840, MNPR-101, uPAR, clinical trials, FDA approval, biopharmaceutical, Nasdaq, capital raise, cybersecurity, intellectual property, corporate governance, drug development, rare disease, cancer imaging, cancer treatment